The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiploma Regulatory News (DPLM)

Share Price Information for Diploma (DPLM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3,748.00
Bid: 3,746.00
Ask: 3,750.00
Change: 38.00 (1.02%)
Spread: 4.00 (0.107%)
Open: 3,730.00
High: 3,764.00
Low: 3,706.00
Prev. Close: 3,710.00
DPLM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition

20 Apr 2017 07:00

RNS Number : 7823C
Diploma PLC
20 April 2017
 

 

DIPLOMA PLC

12 CHARTERHOUSE SQUARE, LONDON EC1M 6AX

TELEPHONE: +44 (0)20 7549 5700

FACSIMILE: +44 (0)20 7549 5715

 

FOR IMMEDIATE RELEASE

 

20 April 2017

 

 

DIPLOMA PLC ACQUIRES ABACUS ALS PTY LTD

FOR MAXIMUM CONSIDERATION OF £15.7m (A$26.0m)

 

Diploma PLC, the international group of businesses supplying specialised technical products and services, is pleased to announce the acquisition of 100% of Abacus ALS Pty Ltd ("Abacus").

 

Abacus is a long-established supplier of clinical diagnostics instrumentation and consumables to the Pathology and Life Sciences sectors. Abacus has particular strengths in Immunology and Biochemistry testing, supplying to both the public and private laboratories in Australia and New Zealand. Abacus also supplies to research and educational institutions, blood donor services and specialist centres including IVF and veterinary laboratories.

 

The business employs 44 staff across its principal locations in Brisbane, Australia and Auckland, New Zealand and the existing management team will remain with the business.

 

Abacus's audited revenues in the year ended 30 June 2016 were ca. £13.6m (A$22.6m) and the audited profit before tax was ca. £1.5m (A$2.5m), after charging losses of discontinued businesses and other non-recurring expenses. After adjusting for these exceptional items, underlying operating profit was ca. £1.8m (A$3m). Audited gross assets at 30 June 2016 were £5.6m (A$9.2m).

 

The initial cash consideration, including net debt acquired but before acquisition costs, is £13.6m (A$22.5m) which will be met from the Group's existing cash resources and revolving bank credit facility. This may be subject to minor adjustment based on the net assets at completion. Further deferred consideration up to a maximum of £2.1m (A$3.5m) may be payable in 2017 depending on the operating profit out-turn of the business in the year ending 30 June 2017.

 

The Board expects this acquisition to be immediately earnings enhancing to the Group and will be reported as part of the Life Sciences activities.

 

Bruce Thompson, Chief Executive of Diploma PLC said:

 

"This acquisition fits well with Diploma's strategy of building a larger, broader based Healthcare business with core strengths in Clinical Diagnostics and Surgical Products. Abacus has a good fit with our existing Healthcare businesses in Australia and New Zealand and opens up further growth opportunities."

 

 

 

 

 

 

 

 

 

For further enquiries please contact:

 

Diploma PLC -

+44 (0)20 7549 5700

Bruce Thompson, Chief Executive Officer

 

Nigel Lingwood, Group Finance Director

 

 

 

Tulchan Communications -

+44 (0)20 7353 4200

David Allchurch

 

Martin Robinson

 

 

 

 

 

NOTE TO EDITORS:

 

Diploma PLC is an international group of businesses supplying specialised technical products and services to the Life Sciences, Seals and Controls industries.

 

Diploma's businesses are focussed on supplying essential products and services which are funded by the customers' operating rather than their capital budgets, providing recurring income and stable revenue growth.

 

Our businesses then design their individual business models to closely meet the requirements of their customers, offering a blend of high quality customer service, deep technical support and value adding activities. By supplying essential solutions, not just products, we build strong long term relationships with our customers and suppliers, which support attractive and sustainable margins.

 

Finally we encourage an entrepreneurial culture in our businesses through our decentralised management structure. We want our managers to feel that they have the freedom to run their own businesses, while being able to draw on the support and resources of a larger group. These essential values ensure that decisions are made close to the customer and that the businesses are agile and responsive to changes in the market and the competitive environment.

 

The Group employs ca. 1,600 employees and its principal operating businesses are located in the UK, Northern Europe, North America and Australia.

 

Over the last five years, the Group has grown adjusted earnings per share at an average of ca. 8% p.a. through a combination of organic growth and acquisitions. Diploma is a member of the FTSE 250 with a market capitalisation of ca. £1.2bn.

 

 

Further information on Diploma PLC is available at www.diplomaplc.com

 

LEI: 213800OG17VYG8FGR19

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQOKCDKABKDBQD
Date   Source Headline
16th Jan 20194:19 pmRNSResult of AGM
16th Jan 20197:01 amRNSDirectorate Change
16th Jan 20197:00 amRNSTrading Statement
7th Dec 20184:09 pmRNSDirector/PDMR Shareholding
7th Dec 20183:00 pmRNSAnnual Financial Report & Notice of AGM
27th Nov 20184:26 pmRNSDirector/PDMR Shareholding
19th Nov 20187:00 amRNSFinal Results
12th Oct 20187:00 amRNSAcquisition
3rd Sep 20184:45 pmRNSBoard Committee Change
29th Aug 20187:01 amRNSDirectorate Change
29th Aug 20187:00 amRNSTrading Statement
22nd Aug 20187:00 amRNSAcquisition
10th Jul 20181:46 pmRNSHolding(s) in Company
12th Jun 20182:59 pmRNSHolding(s) in Company
16th May 20182:41 pmRNSDirector Declaration
15th May 20184:20 pmRNSDirector/PDMR Shareholding
15th May 20184:09 pmRNSDirector/PDMR Shareholding
14th May 20187:00 amRNSHalf-year Report
9th May 20187:00 amRNSDirectorate Change
23rd Apr 20187:00 amRNSDirectorate Change
28th Mar 20187:00 amRNSTrading Update
21st Mar 20189:30 amRNSHolding(s) in Company
20th Mar 20184:00 pmRNSHolding(s) in Company
6th Feb 20189:49 amRNSDirector/PDMR Shareholding
30th Jan 20187:00 amRNSDirectorate Change
23rd Jan 20184:00 pmRNSDirector Declaration
17th Jan 20184:30 pmRNSResult of AGM
17th Jan 20187:00 amRNSTrading Statement
28th Dec 20174:13 pmRNSDirector/PDMR Shareholding
12th Dec 20173:18 pmRNSHolding(s) in Company
8th Dec 20173:00 pmRNSAnnual Financial Report & Notice of AGM
27th Nov 20174:00 pmRNSDirector/PDMR Shareholding
20th Nov 20177:00 amRNSFinal Results
25th Oct 201710:00 amRNSHolding(s) in Company
25th Oct 20179:50 amRNSHolding(s) in Company
29th Sep 20174:00 pmRNSDirector Declaration
27th Sep 20177:00 amRNSDirectorate Change
26th Sep 201712:41 pmRNSHolding(s) in Company
5th Sep 20177:00 amRNSResult of Statutory Audit Tender
30th Aug 20177:00 amRNSTrading Update
17th Aug 20173:29 pmRNSHolding(s) in Company
16th Jun 20179:00 amRNSHolding(s) in Company
14th Jun 20174:05 pmRNSDirector/PDMR Shareholding
15th May 20177:00 amRNSHalf-year Report
20th Apr 20177:00 amRNSAcquisition
18th Apr 20179:44 amRNSHolding(s) in Company
30th Mar 20177:00 amRNSTrading Update
23rd Mar 20173:05 pmRNSDirector/PDMR Shareholding
13th Mar 20172:08 pmRNSHolding(s) in Company
16th Feb 20175:10 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.